It has been reported that a major advantage of CSPG4-CAR-T cell therapy is its ability to target both primary TNBC cells and cancer-associated fibroblasts (CAFs) because CSPG4 is highly expressed on stromal cells in the TNBC TME (103). This evidence concerns the gene CSPG4 and cancer.